In a real life situation, where many NAD+ precursors could be present in a tumor environment, blocking only one pathway of NAD+ synthesis would not be sufficient and this could greatly contribute to the loss of the therapeutic efficacy of NAMPT inhibitors. The gene discussed is NAMPT; the disease is neoplasm.